雪榕生物(300511) - 2021 Q3 - 季度财报

Financial Performance - Revenue for Q3 2021 was ¥500,488,155.72, a decrease of 11.84% compared to the same period last year[5] - Net profit attributable to shareholders was -¥44,687,522.97, a decline of 173.06% year-over-year[5] - Total operating revenue for Q3 2021 was ¥1,429,298,969.19, a decrease from ¥1,563,472,564.20 in the previous period[23] - The net profit for Q3 2021 was a loss of ¥143,764,632.81, compared to a profit of ¥202,162,091.60 in the same period last year[25] - The total comprehensive income for the period was -155,792,313.28 CNY, compared to 195,597,027.22 CNY in the previous period[26] - The company reported a basic and diluted earnings per share of -0.27 CNY, compared to 0.50 CNY and 0.48 CNY respectively in the previous period[26] - The company reported a significant increase in research and development expenses to ¥12,437,740.95 from ¥9,584,250.06[23] - The company reported a decrease in comprehensive income attributable to the parent company, which was -122,303,247.98 CNY compared to 212,693,608.57 CNY in the previous period[26] Cash Flow - Cash flow from operating activities was ¥70,975,793.40, down 80.38% from the previous year[10] - The company reported a significant decrease in cash flow from financing activities, down 98.12% to ¥8,434,422.20[10] - The net cash flow from operating activities was 70,975,793.40 CNY, a decrease of 80.4% from 361,815,630.31 CNY in the previous period[29] - Cash inflow from investment activities was 702,836,873.18 CNY, while cash outflow was 1,227,721,642.29 CNY, resulting in a net cash flow of -524,884,769.11 CNY[29] - The cash inflow from financing activities was 744,342,739.85 CNY, while cash outflow was 735,908,317.65 CNY, resulting in a net cash flow of 8,434,422.20 CNY[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,448,226,727.95, a decrease of 2.55% from the end of the previous year[5] - The company's total assets decreased to ¥4,448,226,727.95 from ¥4,564,612,500.09[22] - Current liabilities increased to ¥1,423,564,839.26 from ¥1,385,109,958.90[21] - The company's equity attributable to shareholders was ¥2,034,016,179.45, with total equity at ¥2,022,814,796.36[34] - Long-term borrowings decreased to ¥494,614,519.39 from ¥517,774,582.86[21] - The total non-current liabilities were ¥1,156,687,744.83[34] Shareholder Information - The total number of common shareholders at the end of the reporting period is 39,508[12] - The largest shareholder, Yang Yongping, holds 30.12% of the shares, totaling 133,085,500 shares[12] - The company has a total of 126,178,519 restricted shares, with 50,000 shares released during the period[15] - The total number of restricted shares held by Yang Yongping is 99,814,125, which are locked due to executive restrictions[15] - The company has a total of 8,141,000 restricted shares remaining after the release of shares during the period[15] Other Financial Metrics - The weighted average return on equity was -2.36%, a decrease of 5.54% compared to the previous year[5] - The company recorded a credit impairment loss of ¥2,198,231.55, down from ¥2,496,696.73 in the previous period[25] - The company experienced a foreign exchange loss of -6,913,514.64 CNY during the period[26] - The company paid 363,377,706.94 CNY in employee compensation, an increase from 311,928,178.12 CNY in the previous period[29] Stock Issuance and Compliance - The company received approval from the China Securities Regulatory Commission for a stock issuance to specific investors on March 24, 2021[16] - The company’s stock issuance plan is in compliance with the requirements set by the Shenzhen Stock Exchange[16] - The company’s stock price for conversion remains unchanged at ¥11.77 per share after a minor share repurchase[16] Construction and Development - The company experienced a significant increase in construction in progress, rising by 88.53% to ¥230,113,403.60[9]